<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637832</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000588042</org_study_id>
    <secondary_id>USCTU-SCHRIFT-06-DOG05-44</secondary_id>
    <secondary_id>USCTU-SCHRIFT</secondary_id>
    <secondary_id>USCTU-RHM-CAN0542</secondary_id>
    <secondary_id>EUDRACT 2007-000222-51</secondary_id>
    <secondary_id>EU-20819</secondary_id>
    <nct_id>NCT00637832</nct_id>
  </id_info>
  <brief_title>Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma</brief_title>
  <official_title>Short Chemo Radiotherapy in Follicular Lymphoma Trial of 90Y Ibritumomab Tiuxetan (ZevalinTM) as Therapy for First and Second Relapse in Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different&#xD;
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and&#xD;
      help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in&#xD;
      different ways to stop the growth of cancer cells, either by killing the cells or by stopping&#xD;
      them from dividing. Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab&#xD;
      tiuxetan, can find cancer cells and carry cancer-killing substances to them without harming&#xD;
      normal cells. Giving rituximab together with combination chemotherapy and yttrium Y 90&#xD;
      ibritumomab tiuxetan may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving rituximab together with combination&#xD;
      chemotherapy and yttrium Y 90 ibritumomab tiuxetan works in treating patients with relapsed&#xD;
      follicular non-Hodgkin lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate the response rates in patients with relapsed follicular non-Hodgkin lymphoma&#xD;
           treated with short-duration rituximab and combination chemotherapy (R-chemo) followed by&#xD;
           rituximab and yttrium Y 90 ibritumomab tiuxetan.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the duration of response in patients treated with this regimen.&#xD;
&#xD;
        -  To evaluate the quality of response in order to determine the conversion rate from&#xD;
           partial response to complete response in patients treated with this regimen.&#xD;
&#xD;
        -  To evaluate the toxicity of yttrium Y 90 ibritumomab tiuxetan when administered after 3&#xD;
           courses of R-chemo.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Chemoimmunotherapy (R-CHOP or R-CVP): Patients receive R-CHOP comprising rituximab IV,&#xD;
           cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine IV on day 1 and oral&#xD;
           prednisolone on days 1-5. Alternatively, patients who have already been exposed to prior&#xD;
           tolerance doses of anthracyclines receive R-CVP comprising rituximab IV,&#xD;
           cyclophosphamide IV, and vincristine IV on day 1 and oral prednisolone on days 1-5.&#xD;
           Treatment repeats every 3 weeks for up to 3 courses.&#xD;
&#xD;
      Patients with objective evidence of response on CT scan or those with &lt; 25% bone marrow&#xD;
      involvement and no signs of bone marrow hypocellularity (&lt; 15%) on bone marrow biopsy proceed&#xD;
      to radioimmunotherapy.&#xD;
&#xD;
        -  Radioimmunotherapy: Four to 6 weeks after completion of R-CHOP or R-CVP, patients&#xD;
           receive rituximab IV followed no more than 4 hours later by yttrium Y 90 ibritumomab&#xD;
           tiuxetan IV over 10 minutes.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate, including combined complete response and partial response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration in patients with responding disease</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 ibritumomab tiuxetan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed grade 1, 2, or 3 follicular non-Hodgkin lymphoma&#xD;
&#xD;
               -  Stage II, III, or IV disease (according to the Ann Arbor staging system)&#xD;
&#xD;
          -  CD20-positive disease&#xD;
&#xD;
          -  Initial disease bulk ≤ 10 cm&#xD;
&#xD;
          -  In first or second relapse after prior treatment with a rituximab-containing&#xD;
             chemotherapy regimen (R-chemo) or chemotherapy alone&#xD;
&#xD;
               -  Relapse must have occurred ≥ 6 months after completion of R-chemo&#xD;
&#xD;
                    -  Relapse that occurred &lt; 6 months after completion of chemotherapy alone&#xD;
                       allowed&#xD;
&#xD;
          -  Has at least one of the following symptoms requiring initiation of treatment:&#xD;
&#xD;
               -  Nodal mass &gt; 5 cm in its greater diameter&#xD;
&#xD;
               -  B symptoms&#xD;
&#xD;
               -  Elevated serum lactate dehydrogenase (LDH) or β2-microglobulin&#xD;
&#xD;
               -  Involvement of ≥ 3 nodal sites (each with a diameter &gt; 3 cm)&#xD;
&#xD;
               -  Symptomatic splenic enlargement&#xD;
&#xD;
               -  Compressive syndrome&#xD;
&#xD;
          -  No primary refractory disease&#xD;
&#xD;
          -  No large pleural or peritoneal effusions&#xD;
&#xD;
          -  No CNS disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 1,000/mm³&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 times ULN&#xD;
&#xD;
          -  AST &lt; 5 times ULN&#xD;
&#xD;
          -  No active obstructive hydronephrosis&#xD;
&#xD;
          -  No evidence of active infection requiring IV antibiotics&#xD;
&#xD;
          -  No advanced heart disease or other serious illness that would preclude study&#xD;
             evaluation&#xD;
&#xD;
          -  No known HIV infection&#xD;
&#xD;
          -  No human anti-mouse antibody (HAMA) reactivity&#xD;
&#xD;
          -  No known hypersensitivity to murine antibodies or proteins&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 12 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No other prior malignancy, except for adequately treated skin cancer, cervical cancer&#xD;
             in situ, or other cancer for which the patient has been disease-free for 5 years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior investigational drugs and recovered&#xD;
&#xD;
          -  No prior radioimmunotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim Illidge</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christie NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-845-226-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre at Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>England</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-182-382-6111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dorset Cancer Centre</name>
      <address>
        <city>Poole Dorset</city>
        <state>England</state>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-120-266-5511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-238-079-8934</phone>
      <email>kc8@soton.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-207-377-7000</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>March 14, 2008</study_first_submitted>
  <study_first_submitted_qc>March 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>October 6, 2009</last_update_submitted>
  <last_update_submitted_qc>October 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2009</last_update_posted>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

